# South America Sacroiliitis Market > South America Sacroiliitis Market Research Report By Diagnosis (Imaging Tests, Anesthetic Injections), By Treatment (Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation), By End User (Hospitals, Diagnostic Centers) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.9% - **2024:** $ 88 Million - **2025:** $ 96.71 Million - **2035:** $ 248.5 Million - **Key Players:** AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR), UCB S.A. (BE) **Report ID:** MRFR/HC/55024-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-sacroiliitis-market-56790 --- ## Market Summary ## **South America Sacroiliitis Market Overview** As per MRFR analysis, the South America Sacroiliitis Market Size was estimated at 24.46 (USD Million) in 2023. The South America Sacroiliitis Market Industry is expected to grow from 29.13(USD Million) in 2024 to 155.77 (USD Million) by 2035. The South America Sacroiliitis Market CAGR (growth rate) is expected to be around 16.465% during the forecast period (2025 - 2035). **Key South America Sacroiliitis Market Trends Highlighted** The South America Sacroiliitis Market has been experiencing notable trends recently. A key market driver is the increasing incidence of sacroiliitis due to conditions like ankylosing spondylitis and other inflammatory diseases, which are becoming more prevalent in the region. Health authorities in countries such as Brazil and Argentina have acknowledged the rising number of patients facing chronic back pain linked to sacroiliac joint inflammation. Additionally, the expanding awareness about this condition among healthcare professionals and patients is encouraging early diagnosis and treatment interventions, thus meeting a critical healthcare gap and driving the market forward. Opportunities to be explored include the enhancement of healthcare infrastructure and improved access to specialized care across South America. Governments have been investing in healthcare initiatives, focusing on training healthcare providers to manage musculoskeletal disorders effectively. The collaboration between pharmaceutical companies and local governments can lead to the development of region-specific treatments, which will cater to the unique healthcare challenges faced by South American populations, particularly in remote and underserved areas. In recent times, there has been a growing trend toward the use of minimally invasive surgical techniques and biological therapies in treating sacroiliitis. Clinics and hospitals in major urban centers are increasingly adopting these advanced treatment modalities, providing patients with options that lead to quicker recovery times and less postoperative pain. The rise of telemedicine in the region also facilitates remote consultations and follow-ups, expanding patient access to specialists and tailored care plans. Overall, these trends highlight a dynamic and evolving landscape for the South America Sacroiliitis Market, driven by a commitment to improving patient outcomes in the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Sacroiliitis Market Drivers** **Increasing Prevalence of Sacroiliitis in South America** The rising prevalence of sacroiliitis in South America is a major factor driving the South America Sacroiliitis Market Industry. According to recent research, chronic inflammation of the sacroiliac joints has increased, with about 2 million people in Brazil alone suffering from disorders such as ankylosing spondylitis and other rheumatic diseases.  This trend is consistent with statistics from the World Health Organization, which indicated that 14.2% of the South American population suffers from arthritis-related diseases, increasing the demand for better diagnostic and treatment choices. Major organizations such as the Brazilian Society of Rheumatology serve to raise awareness by advocating improved diagnostic and treatment procedures, hence driving market growth for sacroiliitis-related products and therapies throughout the area. **Growing Investment in Healthcare Infrastructure** The investment in healthcare infrastructure across South America is another critical driver for the South America Sacroiliitis Market Industry. Governments in countries such as Argentina and Colombia are boosting healthcare spending significantly, aiming to improve patient access to necessary services.  For example, Argentina's healthcare budget saw a 12% increase in the last fiscal year, directed at enhancing healthcare facilities and services related to musculoskeletal disorders.This focus is further supported by entities like the Pan American Health Organization, which emphasizing arthritis and musculoskeletal disease management among member states. An improved healthcare framework enhances the ability of patients to receive timely diagnoses and treatment, thus positively impacting the sacroiliitis market growth. **Advances in Research and Development for Treatments** The advancements in Research and Development for innovative treatment options contribute significantly to the growth of the South America Sacroiliitis Market Industry. Pharmaceutical companies and research institutions in South America are increasingly focusing on developing biologics and targeted therapy solutions designed to effectively treat sacroiliitis.  For instance, centers such as the University of So Paulo are conducting substantial clinical trials assessing the safety and efficacy of new therapies, reflecting a 30% increase in R&D funding over the past three years.These developments promise to improve treatment outcomes for patients and are likely to expand market availability, supported by regulatory bodies like ANVISA (National Health Surveillance Agency of Brazil), which streamlines approvals for effective treatments. **South America Sacroiliitis Market Segment Insights** **Sacroiliitis Market Diagnosis Insights** The Diagnosis segment within the South America Sacroiliitis Market is a critical area characterized by its advanced methodologies and techniques. It encompasses key components such as Imaging Tests and Anesthetic Injections, both of which are fundamental for accurate and effective assessment of sacroiliitis. Imaging Tests play a crucial role in the Diagnosis segment, enabling healthcare professionals to visualize and evaluate the sacroiliac joints. These tests are vital as they assist in identifying inflammation, structural deformities, or other conditions linked to sacroiliitis. The advancements in imaging technology, including MRI and CT scans, are leading to improved diagnosis accuracy, which is essential for patient treatment pathways. This technological evolution is driven by the healthcare industry's ongoing focus on enhancing diagnostic capabilities, thereby propelling growth within this segment.In parallel, Anesthetic Injections serve as a significant diagnostic tool that also possesses therapeutic benefits.  They allow for targeted pain relief while simultaneously confirming the sacroiliac joint as the source of pain. By injecting anesthetic agents directly into the joint or surrounding tissues, physicians can assess the effectiveness of pain relief, helping confirm the presence of sacroiliitis. This diagnostic approach not only aids in confirming the diagnosis but can also contribute to a more personalized treatment plan, which is becoming increasingly important in the region. Overall, the growth driver for the Diagnosis segment in the South America Sacroiliitis Market is linked to an increase in the prevalence of sacroiliitis and the growing awareness surrounding its management.  The region has witnessed an uptrend in the recognition of musculoskeletal disorders, which has also spurred an emphasis on effective diagnostic techniques. These trends are significant in shaping the dynamics and expansion opportunities within the market, which reflect a burgeoning healthcare infrastructure and increasing access to advanced diagnostic technologies across South America. Additionally, public health initiatives aimed at raising awareness of sacroiliitis and its impact on quality of life further enhance the demand within the Diagnosis segment. As a result, both Imaging Tests and Anesthetic Injections are positioned to remain key components driving further insights and developments in the overall South America Sacroiliitis Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Sacroiliitis Market Treatment Insights** The Treatment segment of the South America Sacroiliitis Market plays a crucial role in addressing the increasing cases of this condition in the region. With a robust healthcare infrastructure and a rising awareness of chronic pain disorders, the market is experiencing significant advancements, particularly in medications and interventional techniques. Medications remain pivotal as they provide immediate relief to patients; this sub-segment is gaining traction due to increasing incidences of arthritis and back pain. Joint Injections also play a significant role in offering targeted relief, helping to reduce inflammation and pain effectively.Additionally, Joint Fusion and Radiofrequency Denervation are emerging as important procedures, particularly for patients who do not respond well to conservative treatments.  These interventional strategies help improve mobility and quality of life for those suffering from sacroiliitis. As the South American population ages and faces a higher incidence of musculoskeletal disorders, the demand for effective treatment options continues to rise, showcasing the overall growth potential of the South America Sacroiliitis Market in the treatment domain.A comprehensive analysis of South America Sacroiliitis Market segmentation reveals that addressing the treatment needs with innovative solutions can significantly enhance patient outcomes in this evolving landscape. **Sacroiliitis Market End User Insights** The South America Sacroiliitis Market, within its End User segmentation, reveals critical insights regarding the roles of Hospitals and Diagnostic Centers. Hospitals are pivotal in providing comprehensive care for sacroiliitis patients, often equipped with advanced technology and specialists that ensure accurate diagnosis and effective treatment. This setting emphasizes a collaborative approach among multidisciplinary care teams, significantly enhancing patient outcomes. Conversely, Diagnostic Centers play an essential role in the early identification of sacroiliitis through specialized imaging techniques and tests, which are crucial for timely intervention. These centers are increasingly vital in the overall patient journey, facilitating early diagnosis that can significantly alter treatment trajectories. The growth of the healthcare infrastructure in South America, coupled with rising awareness regarding musculoskeletal disorders, is expected to propel demand in both these segments. Moreover, shifting demographics and increasing prevalence of lifestyle-related diseases further support the need for effective healthcare services within this market. The integration of technology and enhanced patient management systems in both hospitals and diagnostic centers underscores their significance, indicating robust prospects for the South America Sacroiliitis Market. **South America Sacroiliitis Market Key Players and Competitive Insights** The South America Sacroiliitis Market is experiencing significant competitive dynamics driven by the rising prevalence of inflammatory diseases and a growing awareness of treatment options among healthcare professionals and patients. With an increasing number of pharmaceutical companies vying for market share, the landscape is characterized by a mix of established multinational corporations and emerging regional players. The competition is further intensified by ongoing advancements in drug development, innovative therapies targeting specific patient demographics, and an emphasis on personalized medicine.  Companies in this market are constantly seeking to enhance their product offerings and expand their geographical footprint, which has resulted in a complex, competitive environment where strategic partnerships and collaborations are increasingly commonplace.Amgen has established a robust presence in the South America Sacroiliitis Market, leveraging its extensive research and development capabilities. The company is known for its strong portfolio, which includes a range of biologics and pharmaceutical products that target inflammatory conditions. Amgen's strengths in South America lie in its established brand recognition, a solid distribution network, and strategic collaborations with local healthcare providers. The company is committed to addressing unmet medical needs in the region and invests significantly in clinical trials aimed at enhancing its product line specifically for sacroiliitis. With a focus on education and awareness campaigns, Amgen seeks to foster stronger relationships with healthcare professionals and patients alike, promoting the understanding of the disease and available treatment options. BristolMyers Squibb has a notable footprint in the South America Sacroiliitis Market, delivering key products that cater to patients suffering from inflammatory and autoimmune conditions. The company’s strength stems from its comprehensive approach to drug development and its strong commitment to research in this area, which has led to breakthrough therapies that address acute symptoms and long-term management of sacroiliitis. BristolMyers Squibb's key products include innovative therapies designed to relieve pain and improve the quality of life for patients in South America. The company's market presence is further enhanced by strategic mergers and acquisitions that have expanded its portfolio and technical expertise, allowing it to respond effectively to local market demands. Through targeted marketing efforts and continuous engagement with healthcare communities, BristolMyers Squibb aims to strengthen its position and enhance the overall treatment landscape for sacroiliitis across the region. **Key Companies in the South America Sacroiliitis Market Include:** - Amgen - BristolMyers Squibb - Merck & Co - GSK - Eli Lilly and Company - AbbVie - UCB - Regeneron Pharmaceuticals - Roche - Teva Pharmaceutical Industries - Sanofi - AstraZeneca - Novartis - Johnson & Johnson - Pfizer **South America Sacroiliitis Market Industry Developments** Recent developments in the South America Sacroiliitis Market reflect an increasing focus on treatment innovations and collaborations among key players. Amgen and Bristol-Myers Squibb are advancing research initiatives, while Eli Lilly and Company are exploring further partnerships to enhance their therapeutic offerings. The market has experienced a significant upsurge in growth, driven by a greater prevalence of sacroiliitis diagnoses across the region.  Merck and Co. recently implemented strategic measures to expand their footprint in Brazil, emphasizing localized clinical trials to optimize their product range. Additionally, in March 2023, Regeneron Pharmaceuticals announced a collaboration with a regional healthcare provider to enhance access to its treatments, underscoring a trend towards increased patient care.  In the past two years, the presence of large multinational firms such as Roche and AstraZeneca has also expanded, ensuring robust competition and a continuous flow of innovations. Furthermore, notable mergers and acquisitions have been absent, but ongoing research and development investments signal a thriving market landscape, which is projected to strengthen in the coming years, responding to the emerging healthcare needs across South America. **South America Sacroiliitis Market Segmentation Insights** **Sacroiliitis Market Diagnosis Outlook** - Imaging Tests - Anesthetic Injections **Sacroiliitis Market Treatment Outlook** - Medications - Joint Injections - Joint Fusion - Radiofrequency Denervation **Sacroiliitis Market End User Outlook** - Hospitals - Diagnostic Centers **Sacroiliitis Market Regional Outlook** - Brazil - Mexico - Argentina - Rest of South America ## Market Drivers ### Growing Prevalence of Sacroiliitis The increasing prevalence of sacroiliitis in South America is a notable driver for the sacroiliitis market. Recent studies indicate that inflammatory diseases, including sacroiliitis, affect approximately 1-2% of the population in this region. This rise in cases is attributed to various factors, including lifestyle changes and genetic predispositions. As more individuals are diagnosed, the demand for effective treatment options and healthcare services is likely to surge. Consequently, pharmaceutical companies and healthcare providers are expected to invest more in research and development, thereby expanding the sacroiliitis market. The growing patient population necessitates enhanced awareness and education about the condition, which could further stimulate market growth. ### Rising Demand for Personalized Medicine The shift towards personalized medicine is emerging as a key driver in the sacroiliitis market. Patients are increasingly seeking tailored treatment plans that consider their unique genetic and environmental factors. This trend is particularly relevant in South America, where diverse populations exhibit varying responses to standard treatments. Pharmaceutical companies are responding by developing targeted therapies that aim to improve efficacy and minimize side effects. The market for personalized medicine is projected to grow at a compound annual growth rate (CAGR) of around 10% in the coming years. This focus on individualized care is likely to enhance patient outcomes and drive further investment in the sacroiliitis market. ### Technological Innovations in Diagnostics Technological advancements in diagnostic tools are significantly impacting the sacroiliitis market in South America. Innovations such as MRI and CT imaging have improved the accuracy of diagnosing sacroiliitis, allowing for earlier detection and treatment. The introduction of these advanced diagnostic methods has led to a more precise understanding of the disease, which is crucial for effective management. As healthcare facilities adopt these technologies, the overall efficiency of treatment protocols is likely to improve, thereby increasing patient satisfaction. Furthermore, the integration of telemedicine in diagnostics may enhance access to specialized care, particularly in remote areas, thus expanding the reach of the sacroiliitis market. ### Government Initiatives to Improve Healthcare Access Government initiatives aimed at improving healthcare access are playing a crucial role in shaping the sacroiliitis market in South America. Policies that promote universal healthcare coverage and subsidize treatments are likely to enhance patient access to necessary medical services. For instance, several countries in the region have implemented programs to reduce out-of-pocket expenses for chronic conditions, including sacroiliitis. This increased accessibility may lead to higher diagnosis rates and, consequently, a greater demand for treatment options. As governments continue to prioritize healthcare reforms, the sacroiliitis market is expected to experience growth driven by improved patient access and affordability. ### Increased Collaboration Among Healthcare Stakeholders Collaboration among healthcare stakeholders is becoming increasingly vital for the growth of the sacroiliitis market in South America. Partnerships between pharmaceutical companies, healthcare providers, and research institutions are fostering innovation and improving treatment options. These collaborations often lead to clinical trials that explore new therapies and enhance understanding of sacroiliitis. Additionally, joint initiatives aimed at raising awareness about the condition are likely to educate both healthcare professionals and patients, thereby increasing diagnosis rates. As these partnerships strengthen, they may contribute to a more robust healthcare ecosystem, ultimately benefiting the sacroiliitis market. ## Future Outlook The [Sacroiliitis Market](https://www.marketresearchfuture.com/reports/sacroiliitis-market-6290) is projected to grow at a 9.9% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in biologics and targeted therapies for enhanced efficacy - Expansion of educational programs for healthcare professionals on sacroiliitis management By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Functional Imaging (Largest) vs. Diagnostic Imaging (Fastest-Growing) In the segment of application insights, Functional Imaging holds the largest share, reflecting its vital role in the diagnosis and management of sacroiliitis conditions. Following closely, Diagnostic Imaging is gaining traction as a crucial component in clinical decision-making, showcasing a competitive market landscape. The diverse applications of these imaging techniques highlight the importance they hold in improving patient outcomes in South America. Growth trends indicate that Diagnostic Imaging is emerging as the fastest-growing segment, driven by advancements in technology and increased awareness of sacroiliitis-related conditions. Factors such as rising healthcare investments and the expanding presence of imaging facilities are propelling the demand for these services. This trend is expected to continue, enhancing overall patient care and supporting innovation in imaging solutions. Functional Imaging (Dominant) vs. Cardiac Imaging (Emerging) Functional Imaging dominates the application segment due to its ability to provide real-time assessments of physiological functions, which is essential for the effective evaluation of sacroiliitis. Its technological advantages allow for comprehensive visualization of patient conditions, leading to better diagnostic accuracy. On the other hand, Cardiac Imaging is emerging prominently as healthcare providers recognize its potential in understanding related complications, thereby expanding the scope of imaging applications in sacroiliitis management. The continuous enhancement in imaging technologies and techniques is likely to further position Cardiac Imaging as a significant player in this market segment. ### By Type: Closed MRI Systems (Largest) vs. Open MRI Systems (Fastest-Growing) In the South America sacroiliitis market, Closed MRI Systems currently capture the largest share, proving their critical role in accurate diagnostics and treatment planning. In comparison, Open MRI Systems are emerging rapidly due to their patient-friendly design and increased accessibility, appealing to both medical professionals and patients. Growth drivers for these segments include advancements in MRI technology, increasing investment in healthcare infrastructure, and a rising awareness of early diagnosis of sacroiliitis. Closed MRI Systems continue to be favored for their image quality, while the growing popularity of Open MRI Systems reflects a shift towards less claustrophobic patient experiences, indicating a dynamic evolution in this space. Closed MRI Systems (Dominant) vs. Open MRI Systems (Emerging) Closed MRI Systems are presently the dominant segment in the market, characterized by their high-resolution imaging capabilities and comprehensive diagnostic features. They are widely adopted in hospitals and specialized clinics, where accurate diagnosis is paramount. In contrast, Open MRI Systems are seen as an emerging segment that caters to a growing demand for more patient-centric approaches. Their design allows more space and comfort, significantly reducing anxiety among patients during imaging procedures. As such, Open MRI Systems are expected to witness increased adoption, especially in outpatient settings, as healthcare providers look to enhance patient satisfaction while maintaining diagnostic efficacy. ### By Field Strength: High Field MRI (Largest) vs. Low Field MRI (Fastest-Growing) In the current landscape, High Field MRI holds the largest market share within the segment, primarily due to its advanced imaging capabilities and superior diagnostic accuracy. Contrastingly, Low Field MRI, while smaller in market share, is gaining significant traction owing to its lower costs and accessibility in rural areas. Mid Field MRI occupies a middle ground, showing stable demand but lacking the rapid growth seen in Low Field MRI. The growth trends for this segment are influenced by technological advancements and increasing healthcare needs across the region. As healthcare providers seek cost-effective yet efficient solutions, the demand for Low Field MRI is expected to surge, making it the fastest-growing segment. Meanwhile, High Field MRI continues to dominate due to its unparalleled detail in imaging, catering to more complex diagnostic requirements. High Field MRI (Dominant) vs. Low Field MRI (Emerging) High Field MRI technology has established itself as the dominant force within the field strength segment, appreciated for its ability to provide high-resolution images and detailed anatomical insights. This variant is primarily utilized in specialized medical facilities where precise diagnostics are critical. On the other hand, Low Field MRI represents an emerging segment, appealing to facilities aiming to manage costs without compromising essential diagnostic capabilities. The affordability and operational simplicity of Low Field MRI make it attractive for expanding healthcare access, especially in less urbanized regions, creating a diverse dynamic between both segment values. ### By End User: Hospitals (Largest) vs. Diagnostic Imaging Centers (Fastest-Growing) In the South America sacroiliitis market, the distribution of market share among the End User segment shows that Hospitals hold a significant portion, marking them as the largest contributors in the industry. Diagnostic Imaging Centers, while not leading, are rapidly gaining traction, highlighting a shift towards specialized diagnostic facilities that cater specifically to sacroiliitis patients. Research Institutes also play a crucial role, albeit with a smaller market share, focusing primarily on innovative treatment alternatives and research advancements. The growth trends within this segment indicate a robust demand for specialized care in sacroiliitis management. Hospitals continue to expand their services and invest in advanced technologies to enhance patient outcomes, while Diagnostic Imaging Centers are emerging as key players due to increased referrals for imaging studies. The rising prevalence of chronic inflammatory conditions is also driving research activities in institutes, which are crucial for developing new therapies and improving patient care protocols. Hospitals: Dominant vs. Diagnostic Imaging Centers: Emerging Hospitals serve as the dominant force in the End User segment, providing a comprehensive range of services including diagnosis, treatment, and rehabilitation for sacroiliitis. They are equipped with advanced imaging technologies and a multidisciplinary team of healthcare professionals, making them essential for managing complex cases. In contrast, Diagnostic Imaging Centers are emerging with a focused approach, providing specialized imaging services that enhance diagnostic accuracy and patient accessibility. This segment is rapidly evolving, aiming to reduce waiting times and improve the patient experience, offering state-of-the-art facilities tailored for precise assessments of sacroiliitis. ## Regional Market Share Analysis ### Brazil : Robust Growth and Demand Trends Brazil holds a commanding 40.0% market share in the South American sacroiliitis market, valued at approximately $200 million. Key growth drivers include increasing prevalence of autoimmune diseases and enhanced awareness of sacroiliitis among healthcare professionals. Government initiatives, such as the National Health Policy, promote better access to treatment, while ongoing investments in healthcare infrastructure bolster service delivery and patient care. Regulatory frameworks are evolving to support innovative therapies, further stimulating market growth. ### Mexico : Growing Awareness and Treatment Access Mexico accounts for 20.0% of the South American sacroiliitis market, with a value nearing $100 million. The rise in demand is driven by increasing healthcare access and a growing population of patients diagnosed with inflammatory diseases. Regulatory bodies are actively working to streamline drug approvals, enhancing the availability of treatment options. Additionally, public health campaigns are raising awareness about sacroiliitis, contributing to higher diagnosis rates and treatment uptake. ### Argentina : Focus on Patient-Centric Care Argentina holds a 15.0% share of the sacroiliitis market, valued at around $75 million. The market is driven by a focus on patient-centric care and the introduction of new biologic therapies. Government policies are increasingly supportive of innovative treatments, with initiatives aimed at improving healthcare access for chronic disease management. The demand for effective treatment options is rising, particularly in urban areas where healthcare facilities are more advanced. ### Rest of South America : Varied Demand Across Regions The Rest of South America represents a 13.0% market share in the sacroiliitis sector, valued at approximately $65 million. This sub-region faces unique challenges, including varying healthcare infrastructure and regulatory environments. Demand is influenced by local disease prevalence and access to treatment options. Countries like Chile and Colombia are emerging markets, with increasing investments in healthcare infrastructure and awareness campaigns aimed at improving diagnosis and treatment of sacroiliitis. ## Competitive Benchmarking The sacroiliitis market exhibits a dynamic competitive landscape characterized by a blend of innovation, strategic partnerships, and regional expansion. Key players such as AbbVie Inc (US), Johnson & Johnson (US), and Novartis AG (CH) are actively shaping the market through their focused operational strategies. AbbVie Inc (US) has positioned itself as a leader in biologics, emphasizing research and development to enhance treatment options for sacroiliitis. Meanwhile, Johnson & Johnson (US) has been pursuing strategic collaborations to bolster its product pipeline, particularly in immunology, which is crucial for addressing inflammatory conditions like sacroiliitis. Novartis AG (CH) appears to be concentrating on digital transformation initiatives, aiming to leverage technology for improved patient engagement and treatment adherence, thereby enhancing its competitive edge.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive environment is shaped by the collective actions of these key players, who are increasingly focusing on sustainability and efficiency in their operations. In October AbbVie Inc (US) announced a significant investment in a new research facility dedicated to the development of novel therapies for autoimmune diseases, including sacroiliitis. This strategic move underscores AbbVie's commitment to innovation and positions the company to potentially lead in the development of next-generation treatments. The establishment of this facility is likely to enhance AbbVie's research capabilities and accelerate the introduction of new therapies to the market. In September Johnson & Johnson (US) entered into a partnership with a leading biotechnology firm to co-develop a new biologic therapy targeting sacroiliitis. This collaboration is indicative of Johnson & Johnson's strategy to expand its therapeutic offerings and leverage external expertise to enhance its product portfolio. Such partnerships may facilitate faster development timelines and broaden access to innovative treatments for patients. In August Novartis AG (CH) launched a digital health platform aimed at improving patient outcomes in chronic inflammatory diseases, including sacroiliitis. This initiative reflects Novartis's focus on integrating technology into healthcare delivery, potentially transforming how patients manage their conditions. By enhancing patient engagement through digital tools, Novartis may improve treatment adherence and overall health outcomes, thereby solidifying its market position. As of November the competitive trends in the sacroiliitis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This shift suggests that companies that prioritize research, digital transformation, and strategic partnerships will be better positioned to thrive in the evolving landscape. ## Recent News & Developments Recent developments in the South America Sacroiliitis Market reflect an increasing focus on treatment innovations and collaborations among key players. Amgen and Bristol-Myers Squibb are advancing research initiatives, while Eli Lilly and Company are exploring further partnerships to enhance their therapeutic offerings. The market has experienced a significant upsurge in growth, driven by a greater prevalence of sacroiliitis diagnoses across the region.  Merck and Co. recently implemented strategic measures to expand their footprint in Brazil, emphasizing localized clinical trials to optimize their product range. Additionally, in March 2023, Regeneron Pharmaceuticals announced a collaboration with a regional healthcare provider to enhance access to its treatments, underscoring a trend towards increased patient care.  In the past two years, the presence of large multinational firms such as Roche and AstraZeneca has also expanded, ensuring robust competition and a continuous flow of innovations. Furthermore, notable mergers and acquisitions have been absent, but ongoing research and development investments signal a thriving market landscape, which is projected to strengthen in the coming years, responding to the emerging healthcare needs across South America. ## Report Scope | MARKET SIZE 2024 | 88.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 96.71(USD Million) | | MARKET SIZE 2035 | 248.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Novartis AG (CH), Pfizer Inc (US), Roche Holding AG (CH), Sanofi S.A. (FR), UCB S.A. (BE) | | Segments Covered | Application, Type, Field Strength, End User | | Key Market Opportunities | Emerging biologics and personalized therapies present growth potential in the sacroiliitis market. | | Key Market Dynamics | Rising demand for innovative therapies in sacroiliitis drives competitive dynamics and regulatory adaptations in South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What was the market valuation for sacroiliitis in 2024?** A: The market valuation for sacroiliitis was $88.0 Million in 2024. **Q: What is the projected market valuation for sacroiliitis by 2035?** A: The projected market valuation for sacroiliitis is $248.5 Million by 2035. **Q: What is the expected CAGR for the sacroiliitis market during 2025 - 2035?** A: The expected CAGR for the sacroiliitis market during 2025 - 2035 is 9.9%. **Q: Which companies are key players in the sacroiliitis market?** A: Key players in the sacroiliitis market include AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson, Novartis AG, Pfizer Inc, Roche Holding AG, Sanofi S.A., and UCB S.A. **Q: What are the main application segments in the sacroiliitis market?** A: Main application segments include Diagnostic Imaging, Functional Imaging, Cardiac Imaging, and Oncology Imaging. **Q: What was the valuation for Diagnostic Imaging in 2024?** A: The valuation for Diagnostic Imaging was $20.0 Million in 2024, projected to reach $55.0 Million by 2035. **Q: What types of MRI systems are included in the sacroiliitis market?** A: Types of MRI systems include Closed MRI Systems, Open MRI Systems, and Extremity MRI Systems. **Q: What is the projected valuation for High Field MRI by 2035?** A: The projected valuation for High Field MRI is $113.5 Million by 2035. **Q: Which end users are significant in the sacroiliitis market?** A: Significant end users include Hospitals, Diagnostic Imaging Centers, and Research Institutes. **Q: What was the valuation for Hospitals in 2024?** A: The valuation for Hospitals was $35.0 Million in 2024, expected to grow to $100.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-sacroiliitis-market-56790*